Head-to-head · WeighScore
Ilant Health vs NovoCare Pharmacy
The verdict
Ilant Health takes it — 56.8/100 to 55.2/100, but only just.
Ilant Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Ilant Health is a value-based obesity and cardiometabolic care company distributed through employers and health plans rather than direct cash-pay. NovoCare Pharmacy is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ilant Health | NovoCare Pharmacy |
|---|---|---|
| WeighScore | 56.8/100 | 55.2/100 |
| Grade | C | C |
| Scorecard rank | #408 | #442 |
| Semaglutide | Not disclosed | $349/mo (2.4 mg dose, brand-name) |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #408 · C
Strengths
- Value-based, outcomes-driven obesity care model
- Includes GLP-1 medications with transparent drug pricing for sponsors
- Care team of board-certified obesity providers and behavioral specialists
- Dietitians and peer navigators support adherence
- Data-driven stratification targets the right interventions
Where it loses points
- Distributed via employers and health plans, not direct cash-pay
- Individuals generally cannot enroll without sponsor coverage
- No public consumer pricing for GLP-1
- Access gated behind organizational buyers
- Not suited to consumers wanting direct-to-door GLP-1
Graded #442 · C
Strengths
- First-party Novo Nordisk pharmacy — the most authoritative branded Wegovy channel
- $199/mo intro pricing on Wegovy 0.25/0.5 mg starter doses (through 6/30/2026), the lowest brand self-pay price
- $349/mo standard self-pay is well below the ~$1,300/mo retail list price
- Ships to all 50 states with no telehealth-platform middleman fees
- Cold-chain logistics handled directly by Novo Nordisk
Where it loses points
- Wegovy only — no Ozempic, no tirzepatide, no compounded GLP-1
- Requires an existing Wegovy prescription — no prescribing clinicians or telehealth intake
- No clinical support included — your own prescriber handles titration and side effects
- Manufacturer-set pricing can change at any time
- $199 pen intro covers only the first 2 fills for new patients (through 6/30/2026); maintenance doses are $349/mo ($399 HD)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.